Dean Quinn
Clinical trial investigator at P3 Research in Wellington, New Zealand, who was a co-author of the resTORbio trials that tested low-dose mTOR inhibitors to strengthen immunity in older adults
P3 Research, Newtown, Wellington, New Zealand (affiliation on PubMed papers) · listed with resTORbio, Boston, on the 2021 trial report
Portrait: Momentum Clinical Research NZ
Dean Quinn is a co-author of two Atlas papers on whether short, low-dose courses of mTOR-blocking drugs can make older people's immune systems work better. In MAN2018, a phase 2a trial in 264 older adults, six weeks of a low-dose combination of BEZ235 and everolimus was followed by fewer reported infections over the next year, more active antiviral genes and a better response to the flu vaccine. MAN2021 then tested BEZ235 alone (renamed RTB101) in two bigger trials. The phase 2b trial (652 people) showed fewer lab-confirmed respiratory infections only in an analysis that was not corrected for multiple testing, and the phase 3 trial (1,024 people) found no difference in its main endpoint. Taken together, these are human trials that gave an early signal and then a negative confirmatory result, a useful lesson in how drug evidence develops.
Trials like these recruit volunteers at specialised research clinics. PubMed lists Quinn at P3 Research in Newtown, Wellington, a clinical trials company in New Zealand, on about ten trial reports, and the 2021 paper also lists him with resTORbio, the Boston company that ran the RTB101 program.
No official profile was found to confirm Quinn's medical training or current position, so this profile is limited to what the publications show.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2018 | H | TORC1 inhibition enhances immune function and reduces infections in the elderly MAN2018 Trial investigator and co-author on the phase 2a study linking a short low-dose course of BEZ235 plus everolimus with fewer infections in older adults. |
| 2021 | H | Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials MAN2021 Co-author, listed with resTORbio and P3 Research, on the phase 2b and phase 3 trials of RTB101, where the phase 3 trial did not confirm a clinical benefit. |
Co-authors in the Atlas 4
People with a profile here who share at least one study with Dean Quinn.
ShowHide
- Joan B. Mannick 2 shared studies Ran early clinical trials of low-dose mTOR inhibitors in older adults, which improved their response to flu vaccination and, in a phase 2a trial, their rate of self-reported infections; a larger phase 3 trial of RTB101 (2021) did not confirm a reduction in respiratory illness. She led this work first at Novartis and then at resTORbio
- David J. Glass Muscle biologist and Regeneron vice president for ageing research, member of the US National Academy of Sciences, who helped discover the muscle-wasting enzymes MuRF1 and MAFbx and co-authored the first trials of low-dose mTOR inhibition in older people
- Lloyd B. Klickstein A physician-scientist who led the clinical studies at Novartis showing that low-dose mTOR inhibitors can boost immune function and cut infections in older adults.
- Sarb Shergill Senior author of the 2021 report of resTORbio's phase 2b and phase 3 trials of the mTOR inhibitor RTB101 to protect older adults from respiratory infections
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.